A Phase 1 interventional study of 40mg lurasidone and placebo in Schizophrenia, sponsored by Sumitomo Pharma (Suzhou) Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-08.
Sponsored by Sumitomo Pharma (Suzhou) Co., Ltd. (formerly part of Sumitomo Pharma Co., Ltd.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.
Among the 39 studies testing lurasidone in Schizophrenia, this one is the 36th largest by enrollment, is one of 2 that started in 2014, is one of 9 in phase 1, and was the 30th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 40 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2014.
This study's enrollment of 14 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 149 across the 39 interventional studies. Of the 38 that completed or were terminated, 27 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma (Suzhou) Co., Ltd., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma (Suzhou) Co., Ltd. is the lead sponsor of 13 studies on the registry; none are open to participants now.
40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd., this one is the 37th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2014, is one of 11 in phase 1, and was the 29th registered.
Sumitomo Pharma Co., Ltd.’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing lurasidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 40 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the pharmacokinetic (PK) characteristics after multiple oral administration of 40 mg lurasidone in healthy Chinese subjects.
To evaluate the safety and tolerance after multiple oral administration of 40 mg lurasidone in healthy Chinese subjects.
Single oral administration of 40 mg study drug lurasidone or placebo after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone or placebo, once daily between Day 4 and Day 8.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.
Drug: 40mg lurasidone
Single oral administration of 40 mg study drug placebo after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg placebo, once daily between Day 4 and Day 8.
Drug: placebo
Lurasidone Cmax
Maximum (peak) observed drug serum concentration.
Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Lurasidone AUC 0-24
Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Lurasidone AUC 0-τ
Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Lurasidone AUC0-∞
Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Lurasidone Tmax
Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Lurasidone λz
Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Lurasidone t1/2
Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Lurasidone MRT
Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Lurasidone CL/F
Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
CLss/F
Time frame: Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8
Lurasidone Vz/F
Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Lurasidone Vzss/F
Time frame: Day 8
Accumulation Ratios Lurasidone,Ratio of Cmax,Ratio of AUC0-∞,Ratio of AUC0-τ,
Time frame: Day 8/Day 1
Summary of Concentration (ng/mL) of Lurasidone - PK Population the Mean (SD) of Day 4 and Day 5
Time frame: Pre-dose (-0.5h) of Day4 and Day5
Summary of Concentration (ng/mL) of Lurasidone - PK Population the Mean (SD) of Day 6 and Day 7
Time frame: Pre-dose (-0.5h) of Day6 and Day7
Lurasidone Cmax
Maximum (peak) observed drug serum concentration.
Time frame: Day8
Lurasidone AUC 0-24
Time frame: Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8
Lurasidone AUC 0-τ
Time frame: Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8
Lurasidone AUC0-∞
Time frame: Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8
Lurasidone Tmax
Time frame: Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8
Lurasidone λz
Time frame: Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8
Lurasidone t1/2
Time frame: Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8
Lurasidone MRT
Time frame: Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8
Total 27 subjects were screened at the clinical site after obtaining informed consent. A total 14 subjects were enrolled into the study and were randomized to lurasidone group (10) and placebo group (4). The data of informed consent from the first subject was 8th April 2014(and that from the last subject was 15th April 2014).
| Milestone | 40mg Lurasidone | Placebo |
|---|---|---|
| Started | 10 | 4 |
| Completed | 9 | 4 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Maximum (peak) observed drug serum concentration.
| ng/mL | 40mg Lurasidone |
|---|---|
| Lurasidone Cmax | 50.2 ± 44.3 |
| ng・h/mL | 40mg Lurasidone |
|---|---|
| Lurasidone AUC 0-24 | 152 ± 33.2 |
| ng・h/mL | 40mg Lurasidone |
|---|---|
| Lurasidone AUC 0-τ | 166 ± 32.4 |
| ng・h/mL | 40mg Lurasidone |
|---|---|
| Lurasidone AUC0-∞ | 179 ± 29.9 |
| h | 40mg Lurasidone |
|---|---|
| Lurasidone Tmax | 1.50 (1.0 to 4.0) |
| 1/h | 40mg Lurasidone |
|---|---|
| Lurasidone λz | 0.0360 ± 20.8 |
| h | 40mg Lurasidone |
|---|---|
| Lurasidone t1/2 | 19.3 ± 20.8 |
| h | 40mg Lurasidone |
|---|---|
| Lurasidone MRT | 12.2 ± 22.7 |
| L/h | 40mg Lurasidone |
|---|---|
| Lurasidone CL/F | 223 ± 29.9 |
| L/h | 40mg Lurasidone |
|---|---|
| CLss/F | 211 ± 27.9 |
| L | 40mg Lurasidone |
|---|---|
| Lurasidone Vz/F | 6198 ± 47.9 |
| L | 40mg Lurasidone |
|---|---|
| Lurasidone Vzss/F | 10618 ± 38.6 |
| Ratios | 40mg Lurasidone |
|---|---|
| Ratio of Cmax | 0.94 (0.75 to 1.18) |
| Ratio of AUC0-∞ | 1.74 (1.59 to 1.90) |
| Ratio of AUC0-τ | 1.25 (1.14 to 1.36) |
| Ratio of Cτ | 2.52 (2.37 to 2.68) |
| ng/ml | 40mg Lurasidone |
|---|---|
| Day4 Pre-dose (-0.5h) | 0.277 ± 31.5 |
| Day5Pre-dose (-0.5h) | 1.15 ± 28.7 |
| ng/ml | 40mg Lurasidone |
|---|---|
| Day6 Pre-dose (-0.5h) | 1.56 ± 27.1 |
| Day7 Pre-dose (-0.5h) | 2.00 ± 27.3 |
Maximum (peak) observed drug serum concentration.
| ng/mL | 40mg Lurasidone |
|---|---|
| Lurasidone Cmax | 48.5 ± 49.4 |
| ng・h/mL | 40mg Lurasidone |
|---|---|
| Lurasidone AUC 0-24 | 190 ± 27.9 |
| ng・h/mL | 40mg Lurasidone |
|---|---|
| Lurasidone AUC 0-τ | 234 ± 27.4 |
| ng・h/mL | 40mg Lurasidone |
|---|---|
| Lurasidone AUC0-∞ | 314 ± 26.6 |
| h | 40mg Lurasidone |
|---|---|
| Lurasidone Tmax | 1.75 (1.0 to 4.0) |
| 1/h | 40mg Lurasidone |
|---|---|
| Lurasidone λz | 0.0199 ± 20.2 |
| h | 40mg Lurasidone |
|---|---|
| Lurasidone t1/2 | 34.9 ± 20.2 |
| h | 40mg Lurasidone |
|---|---|
| Lurasidone MRT | 22.0 ± 19 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 40mg Lurasidone | — | 0/10 (0%) | 10/10 (100%) |
| Placebo | — | 0/4 (0%) | 1/4 (25%) |
| Event | 40mg Lurasidone | Placebo |
|---|---|---|
| SomnolenceNervous system disorders | 10/10 | 0/4 |
| Blood prolactin increasedInvestigations | 6/10 | 1/4 |
| RestlessnessPsychiatric disorders | 6/10 | 0/4 |
| DizzinessNervous system disorders | 4/10 | 1/4 |
| Blood bilirubin increasedInvestigations | 2/10 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 1/10 | 0/4 |
| DyspepsiaGastrointestinal disorders | 1/10 | 0/4 |
| NauseaGastrointestinal disorders | 1/10 | 0/4 |
All subjects who received lurasidone or placebo were included in the safety population. All subjects who received lurasidone and have evaluable PK data were included in the PK analysis population.
| Age, Continuous(years) | 40mg Lurasidone | Placebo | Total |
|---|---|---|---|
| Mean | 27.7 ± 3.74 | 26.5 ± 5.07 | 27.4 ± 3.99 |
| Sex: Female, Male(Participants) | 40mg Lurasidone | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 10 | 4 | 14 |
The record gives a start of Apr 2014, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2019, 5 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma (Suzhou) Co., Ltd. →